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Pathogenesis of mitral regurgitation
a b s t r a c t
Background: Balloon mitral valvotomy (BMV) is a well-established therapeutic modality for
rheumatic mitral stenosis (RMS). However, there are chances of procedural failure and the
more ominous post-procedural severemitral regurgitation. There are only a few prospective
studies, which have evaluated the pathogenicmechanisms for thesemajor complications of
BMV, especially in relation to the subvalvular apparatus (SVA) pathology.
Methods: All symptomatic patients of RMS suitable for BMV by echocardiographic criteria in
a span of 1 year were selected. In addition to the standard echocardiographic assessment of
RMS (Wilkins score and score by Padial et al.), a separate grading and scoring system was
assigned toevaluate theseverityof theSVApathology.TheSVAscorewas 'I',whennoneof the
two SVAs had severe disease, 'II' when one of the two SVAs has severe disease, and 'III' when
both SVAs had severe disease. With these scoring systems, the outcomes of BMV (successful
procedure, failure, and post-proceduralmitral regurgitation) were analyzed. Emergency valve
replacement was performed depending on clinical situation, and in cases of replacement, the
pathology of the excised mitral valves were compared with echocardiographic ﬁndings.
Results: Of the 356 BMVs performed in a year, 43 patients had adverse outcomes in the form
of failed procedure (14 patients) and mitral regurgitation (29 patients). Forty-one among
these had a SVA score of III. The sensitivity and speciﬁcity of the MR score was lesser than
the SVA score (sensitivity 0.34 vs. 1.00, speciﬁcity 0.92 vs. 0.99, respectively). The mitral
valvular morphology in 39 patients who underwent post-procedural valve replacements
correlated well with echocardiography ﬁndings.
Conclusion: It is important to assess the degree of SVA pathology in the conventional
echocardiographic assessment for RMS, as BMV would have adverse events when both
iseased.
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i n d i a n h e a r t j o u rn a l 6 7 ( 2 0 1 5 ) 4 2 8 – 4 3 3 4291. IntroductionBalloonmitral valvotomy (BMV) is thepreferred intervention for
rheumatic mitral stenosis (RMS). However, a successful out-
come is not seen in all the patientswho undergo this procedure
as somepatientsdevelop varying gradesofmitral regurgitation,
while some valves do not yield to balloon dilatation; both
subsets sooner or later may require a surgical intervention. In
this background, themorphology of the diseasedmitral valve is
the most important predictor of the immediate outcome. Two-
dimensional echocardiography (2D-Echo) and color Doppler
(CD) evaluation of the mitral valve with scoring methods have
beendeveloped for patient selection, so as to exclude thosewho
are most likely to develop failure or severe mitral regurgitation
(SMR).1–12 Surprisingly, only a few studies have addressed the
post-procedural problems in a prospective manner; further-
more, very few researchers have correlated the valvular
pathologywith 2D-Echo ﬁndings.13–15 This studywas undertak-
en to analyze the relationship of echocardiographic and/or
pathological features of themitral subvalvular apparatus (SVA)
with reference to adverse outcomes of BMV.
2. Materials and methodsFig. 1 – Parasternal long-axis (PLAX) (A) and short-axis (SAX)
(B) view showing mild SVA pathology (Gr I).This was a 1-year prospective, observational study, conducted
in a tertiary care hospital, and was approved by the hospital
ethics committee. All symptomatic patients of RMS who
fulﬁlled the standard clinical and echocardiographic criteria
for BMV11,15 were included. All these patients underwent
detailed clinical evaluation, which also included chest X-ray
and ECG. In all patients, four independent cardiologists
(blinded for pre- and post-procedural recordings) analyzed
the 2D-Echo and CD images and inter-observer variation was
obtained. The variables assessed included mitral valve score
(Wilkins score (WS) and mitral regurgitation score (MR
score)11,15), mitral valve area (calculated by planimetry and
pressure half-time in apical four-chamber view), and baseline
and post-procedural mitral, aortic, and tricuspid pathologies
(assessed as per European Association of Echocardiography
guidelines17). Scoring was performed prospectively and out-
comeswere assessed by all observers. Intra-observer variation
was assessed by evaluating the recorded image twice.
In addition to the aforementioned variables, a scoring
system based on echocardiographic morphology of SVA
pathology was devised. As mitral valve has two SVAs, each
was assessed individually in the parasternal long axis, short
axis, and apical views. Posteromedial SVA can be imaged in
parasternal long-axis view by tilting the probe toward the left
shoulder. The SVA pathology was graded as: 1. Mild, when
multiple, thickened, discrete chordae were visible just below
commissures (Fig. 1); 2. Moderate, when thickened and fused
chordae form two identiﬁable thick chords below commissure
(Fig. 2), and 3. Severe, when fused chordae appear as a single,
thick chord below the commissure (Fig. 3). Further, SVA
scoring was done as follows: Score I where both SVAs have
mild to moderate disease, Score II where one SVA has severe
disease and the other has mild to moderate disease, and Score
III where both SVAs have severe disease.TheBMVwas performed as per the conventional technique,
using the Inoue balloon (Toray Corporation, Japan) (intended
balloon diameter in mm = height in cm/10 + 10).16 Successful
BMV was deﬁned when all of the following criteria were met:
more than 50% gain in MVA or post-BMV MVA >1.5 cm2, no
more than grade 1 increase in MR or moderate MR, and
complete splitting of at least one commissure.
Failure of BMV and SMR were adverse events. Failure of
BMVwas deﬁned as (1) none of the above criteriaweremet and
(2) there was absence of commissural splitting. SMR following
BMV was deﬁned as immediate post-procedural MR that was
severe grade.17 Patients with adverse events underwent valve
replacement depending on the clinical status. Excised mitral
valves were then compared with echocardiographic ﬁndings.
In the statistical analysis, mean and standard deviation
was calculated for all continuous variables (age, mitral valve
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Fig. 3 – PLAX (A) and SAX (B) showing SVA severe pathology
in a patient who developed anterior mitral leaflet tear.
[(Fig._2)TD$FIG]
Fig. 2 – PLAX (A) and short-axis (B) view showing moderate
(Gr II) SVA pathology. (B) Posteromedial SVAwith moderate
(Gr II) pathology and anterolateral SVA with severe (Gr III)
pathology.
i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) 4 2 8 – 4 3 3430area,mitral valve gradient, etc.).Whenmeanswere compared,
an unpaired 't' test was used and two-tailed 'p' value was
calculated. Outcome variables (success, failures, SMR) were
treated as categorical variables. The Fisher's exact test was
used to compare two qualitative parameters. Inter-observer
and intra-observer variations were calculated with a correla-
tion coefﬁcient.
3. ResultsDuring the study period, 356 patients underwent BMV for
valvular stenosis or restenosis (37 patients), of which 219 were
female patients. The procedure was successful in 313 (88%)
patients, though a subset of patients in this group (70 patients)
developed mild to moderate regurgitation that was managed
conservatively. The remaining 43 patients had adverse out-
comes (Tables 1–3) in the form of failed procedure (14 patients,
3.9%) and SMR (29 patients, 8.1%). The SVA score was III in 41patients, while it was II in 2. Inter-observer and intra-observer
variations for the SVA score were 9% and 6%, respectively.
In all 14 patients with BMV failures, the SVA score was III,
and in addition, themitral valvular leaﬂetswere thick (3 or 4 by
WS). All SMR resulted from leaﬂet tears, anterior mitral leaﬂet
in 23 patients, and the posterior mitral leaﬂet in 6 patients. It
was observed that when SVA score was III and leaﬂets were
thin (1 or 2 byWS), patients developed SMR from leaﬂet tear (16
cases). Also, when SVA score was III and leaﬂets were thick (3
or 4 by WS), both SMR (N = 11) and failure (N = 14) were
observed. In other words, valves leading to SMR or failure have
similar SVA pathology but different leaﬂet thickness. Of 29
patients who developed SMR, 17 had false negative MR score
(59%). Of these, 15 patients were correctly stratiﬁed by SVA
score, and 2 were false negative (7%). False positive results
Table 1 – Patient characteristics (numbers in bracket








Number [females] 43 [28] 313 [191]
Age 33.62 (13.92) 31.51 (10.95) 0.25
NYHA class 2.15 (0.32) 2.09 (0.31) 0.23
Past mitral intervention 7 (16%) 65 (20.7%)
Atrial ﬁbrillation 11 (25%) 73 (23%)
Wilkins score 9.046 (1.74) 7.88 (1.69) <0.0001
MR score 9.88 (1.54) 7.88 (1.39) <0.0001
SVA score 2.90 (0.4) 1.55 (0.49) <0.0001
MR at baseline Gr I 15 (35%) 97 (31%)
MVA (cm2) 0.74 (0.13) 0.77 (0.16) 0.24
MVG (mmHg) 15.16 (3.43) 15.58 (6.09) 0.65
Post-BMV
MVA (cm2) 0.82 (0.09) 1.57 (0.26) <0.0001
MVG (mmHg) 11.37 (1.67) 5.78 (2.6) <0.0001
Table 2A – Outcome of BMV and SVA score (p < 0.0001).
SVA score outcome Adverse event Successful BMV
III 41 0
I or II 2 313
Table 2B – Outcome of BMV and MR score ( p = 0.0008).
MR score outcome Adverse event Successful BMV
10 or more 20 39
Up to 9 23 274
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were good predictors of adverse outcome, the former had
better sensitivity, speciﬁcity, positive predictive value, and
negative predictive values than the latter. Logistic regression
analysis was not possible as all patients having SVA score III
had adverse outcome. Positive and negative likelihood ratios
for SVA score were >10 and <0.1, respectively. It meant
'conclusive or signiﬁcant increase or decrease' in likelihood of
disease, respectively. The values for MR score were 4.3 and 0.7,
respectively. Thismeant 'small increase' or 'minimal decrease'
in likelihood of disease, respectively.
Out of 43 patients experiencing adverse outcome, 39
underwent MVR for various clinical and hemodynamicTable 3 – Adverse events after BMV: SVA score, MR score




vs. up to 9
Fisher's exact test p < 0.0001 p < 0.0001





Sensitivity 1.00 (0.91–1.00) 0.34 (0.22–0.47)
Speciﬁcity 0.99 (0.97–0.99) 0.92 (0.88–0.95)
Positive predictive value 0.95 (0.84–0.99) 0.46 (0.31–0.62)
Negative predictive value 1.00 (0.98–1.00) 0.87 (0.83–0.91)
Positive likelihood ratio Inﬁnity 4.38 (2.58–7.44)
Negative likelihood ratio 0.05 (0.01–0.18) 0.72 (0.6–0.86)
Fig. 4 – Specimen showing (A) mild (Gr I) and severe SVA
(Gr III) pathologies, (B) moderate (Gr II) SVA pathology, and
(C) severe (Gr III) SVA pathology at both sites.
[(Fig._5)TD$FIG]
Fig. 5 – Anterior mitral leaflet tear. Note absence of
calcification or thickening of commissures.
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improvement in symptoms, while 4 patientswith tears did not
give consent. The SVA scoring on echocardiography could be
reafﬁrmed in these cases (Fig. 4). There were 2 perioperative
deaths. The site of leaﬂet tear was conﬁrmed during surgery.
Pathological ﬁndings of SVA were as follows:(a) Mild (Fig. 4A): multiple thick chordae attached to the under
surface of leaﬂet.(b) Moderate (Fig. 4B): a few (2–3) thick chords attached to
under surface of AML; however, fusion was less extensive
than seen in severe SVA disease.(c) Severe (Fig. 4C): extensive fusion and shortening of SVA so
that a single very thick rod-like structurewas visible, and it
looked like AML is directly inserted into papillary muscle.
It was observed that highly ﬁbrotic and/or calciﬁed
commissures had corresponding severe SVA disease (n = 17).
However, severe SVA disease was not always associated with
severe commissural pathology (Fig. 5).4. Discussion
It is an undeniable fact that success is not always the outcome
of BMV. A successful procedure depends on appropriate
selection, which in turn depends on evaluation of the mitral
valvular pathology on echocardiography. However, the criteria
employed do not have high sensitivity and speciﬁcity. The
reasons for this are largely two-fold. Following rheumatic
fever, the post-inﬂammatory processes involve commissures,
leaﬂets, and SVA to a variable extent. Thickening, fusion, and
shortening of chordae tendineae are important pathological
changes in SVA. As disease advances, the chordae tend to fuse
and can appear as a single thick structure, so much so that, at
times, the leaﬂets appear to be directly inserted on papillary
muscles. In addition, asymmetrical involvement of MV is welldescribed, whereby one SVA and commissure can be more
affected than the other.18–21 Besides, there can even be variable
thickening of the leaﬂets. This was noted in the pathological
examination of the excised mitral valves in this study. Hence,
detailed description of every part of the valve, independent of
the other, is necessary. The other important factor is that
though WS and MR scores comment on the severity of SVA
disease, the echocardiographic analyses do not correlate
well with pathology. Also, WS does not take into account
asymmetry of diseased valve, and there is a distinct possibility
of 2 different scores, depending upon which SVA is evaluated.
Similarly, 2 distinct MR scores are possible.5,13 Thus, there is a
lack of standardization. Till date, there is very little pathologi-
cal conﬁrmation for these two scores.
It is stressed that highly ﬁbrotic and calciﬁed commissures
resisted splitting and lead to adverse outcome. However,
during the present study, nearly 60% leaﬂet tears had pliable
leaﬂets and far different commissural morphology. The only
consistent ﬁnding, in these patients, was the SVA score III, i.e.,
both SVAs were with severe disease. It suggests that severely
diseased commissures are just a surrogate marker of severe
SVA disease, which is themain pathological factor responsible
for the outcome. Hence, commissural morphology may not be
the necessary parameter for risk stratiﬁcation if SVApathology
is clearly deﬁned. These factors could be responsible for higher
sensitivity and speciﬁcity of SVA score than MR score. It can
also be the reason for decrease in cutoff value ofMR score from
10 to 8 or 7 by a few researchers.4,5,10,13–16,22
As mentioned earlier, every patient with SVA score II can
have 2 distinct results of MR score and possibly 2 distinct risk
categories. They can be put in higher risk category and denied
the beneﬁt of BMV. However, after evaluating SVA score, better
risk stratiﬁcation was possible and successful outcome of
BMV could be achieved. These ﬁndings could explain high
false positive cases with MR score, which was not observed
for SVA score.
Above ﬁndings were conﬁrmed in vitro by Sadee et al. He
concluded that when SVA was severely diseased, there was
leaﬂet tear. There was no correlation between site of calciﬁca-
tion (commissural or otherwise) and outcome of balloon
dilatation. However, it contradicts importance of parameters
like leaﬂet thickening and commissural morphology, which
were proposed by Padial et al. and Wilkins.5,13,22
Possibly themost important advantage of SVA score is that
it explains outcome after evaluating only one aspect of RMS.
These outcomes, as well as entire scoring, were supported by
pathological evidence. This can help in better standardization
as well as reproducibility of the score. By not considering
commissural or leaﬂet morphology, there was no loss of
sensitivity or speciﬁcity. In fact, it fared better than other (MR
score/WS) scores during head to head comparison. The score
wasnot used in isolation for risk stratiﬁcation of SMR.However,
nearly 88% of patientswith SMR,whoweremissed byMR score,
were correctly diagnosed by SVA score. It also did not miss any
patient, who was correctly diagnosed by MR score.
4.1. Limitations
This is a small observational study with short-term outcome.
All patientswith RMSdidnot undergo BMV to assess validity of
i n d i a n h e a r t j o u rn a l 6 7 ( 2 0 1 5 ) 4 2 8 – 4 3 3 433different scores. It would be unethical to attempt BMV when
both commissures are calciﬁc, because robust data are
available to support current protocol. All SMR were from
leaﬂet tear. The number of either failures or SMRwas less than
30, so they were combined together to calculate statistical
signiﬁcance. Inoue balloon was used exclusively. It may be
difﬁcult to compare our results with other studies, which used
single or double balloon technique and a different formula to
calculate balloon size. Only with a much larger sample size
and successful exclusion of patientswhowould develop leaﬂet
tear, echocardiographic predictors for other mechanisms of
SMR could be evaluated. We have used MR score to predict
adverse event (SMR and failure) though it was designed for
SMR only.
4.2. Conclusion
Conventional 2D echocardiography scoring systemhas greatly
stressed on the inﬂuence of various factors, like SVA
pathology, commissural morphology, and leaﬂet thickening
on outcome of BMV. However, we think that they are
interlinked. Valves do not have uniform pathology; hence, it
may not be logical to give a single score for each parameter
(two SVAs in a valve can have a different pathology; leaﬂet
thickening may not be uniform).
Pathology of SVA is to be the single most important factor
inﬂuencing outcome of BMV, irrespective of commissural
morphology. Both SMR or failures have similar SVA pathology.
The phrase 'severe SVA pathology leads to suboptimal results
of BMV' needs to be redesigned to 'severe disease of both SVAs
apparatus leads to adverse outcomes of BMV'. For this subset
of patients, mitral valve replacement should be the therapy of
choice.
The SV score, Wilkins scores, and MR score of the patients
with adverse events were signiﬁcantly higher than the scores
of patients without adverse events. SVA score was better than
MR score in segregating patients who would develop adverse
events. Age, the presence of MR at baseline, or the MV area at
baseline did not correlate with higher adverse events. Hence,
we propose that every patient undergoing BMV needs to be
evaluatedwith new SVA score to assess risk for adverse events
along with the Wilkins score.
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